A phase II pilot study of fosaprepitant (F) for the rescue of acute nausea and vomiting with moderately (MEC) or highly emetogenic chemotherapy (HEC) in adults.
Joseph S. Bubalo
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Ian D. Schnadig
No relevant relationships to disclose
Gabrielle Meyers
No relevant relationships to disclose
Andy I. Chen
No relevant relationships to disclose
Brandon M. Hayes-Lattin
No relevant relationships to disclose
Christopher W. Ryan
No relevant relationships to disclose
Jocelyn Digregorio
No relevant relationships to disclose
Richard T. Maziarz
No relevant relationships to disclose